Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Alexis Q. Dean, Shen Luo, Julianne D. Twomey, Baolin Zhang
Materialtyp: Artigo
Språk:Inglês
Publicerad: Taylor & Francis Group 2021-01-01
Serie:mAbs
Ämnen:
Antibody–drug conjugate (adc)
monoclonal antibody (mAb)
cytotoxic payload
bioconjugation
cancer therapy
analytics
Länkar:https://www.tandfonline.com/doi/10.1080/19420862.2021.1951427
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk